title: Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?
abstract: OBJECTIVE
  To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, β-ﬁbrinogen -455 G → A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients.
  
  
  METHODS
  Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups.
  
  
  RESULTS
  Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk.
  
  
  CONCLUSIONS
  There is no possible benefit from genetic screening tests regarding VTE in cancer patients.
authors: Department of Biochemistry, Celal Bayar University School of Medicine, Manisa, Turkey.
authors: Ece
authors: E
authors: Onur
authors: Adnan Taner
authors: AT
authors: Kurdal
authors: Berrin
authors: B
authors: Tugrul
authors: Ihsan
authors: I
authors: Iskesen
authors: Pınar
authors: P
authors: Dundar
authors: Fatma
authors: F
authors: Taneli
authors: Cevval
authors: C
authors: Ulman
authors: Ahmet
authors: A
authors: Var
mesh_terms: D004198:Disease Susceptibility; D005260:Female; D005820:Genetic Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011110:Polymorphism, Genetic; D054556:Venous Thromboembolism / Q000150:complications / Q000235:genetics*